Dinah S. Singer, Ph.D.
Dinah S. Singer, Ph.D.
Senior Investigator
Head, Molecular Regulation Section
Director, Division of Cancer Biology, NCI

Dr. Singer’s research has provided novel insights into the molecular mechanisms that regulate MHC class I transcription in vivo. Her most recent studies have identified 1) the mitotic bookmark, BRD4, as a novel kinase that regulates early transcription, linking mitosis and transcription and 2) the transcription factor, TAF7, as a checkpoint regulator of early transcription.

Dr. Singer research program is focused on interrogating the regulatory networks governing transcription to generate an integrated understanding of the interplay between promoter elements and transcription complexes that establish appropriate regulation of gene expression across diverse cellular and tissue environments.

Areas of Expertise
1) molecular biology, 2) immunology, 3) gene expression, 4) biochemistry, 5) animal models

Contact Info

Dinah S. Singer, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 4B-17
Bethesda, MD 20892
301-496-9097
dinah.singer@nih.gov

Molecular Mechanisms Regulating Gene Expression

The long-term goal of our research program is to define the molecular mechanisms regulating gene expression. To that end, the lab focuses on three main areas: 1) analyses of the factors and regulatory mechanisms that govern transcription initiation; 2) core promoter architecture and function in constitutive and activated transcription; 3) the role of epigenetic regulation.

Transcription initiation requires the assembly of a preinitiation complex (PIC), consisting of a set of general transcription factors and RNA polymerase II. The conventional understanding is that the PIC and its components are invariant among genes and cells. However, in studies on regulatory transcription factors, we discovered that the usage of general transcription factors varies in response to extracellular signals. Thus, whereas constitutive expression of a major histocompatibility (MHC) class I gene depends on the general transcription factor TFIID, γ-interferon activated transcription depends instead on the cofactor CIITA, which bypasses the requirement for TFIID. These studies demonstrated the dynamic nature of the factors regulating transcription initiation. This point was further demonstrated in subsequent studies from the lab which discovered a novel role for the TFIID component, TAF7, independent of its interaction with TFIID. Through its interactions with the kinases that phosphorylate RNA polymerase II, TAF7 regulates early steps of transcription.

In recent studies, we discovered that BRD4, a bromodomain family member currently being tested as a therapeutic target in cancer and autoimmune diseases, is a RNA polymerase II kinase essential for transcription. Our studies demonstrated that BRD4 plays a critical role in regulating the early steps of transcription initiation, both through its direct phosphorylation of RNA polymerase II and its interactions with other components of the transcription machinery, including TAF7. These findings suggest novel ways in which BRD4 might be therapeutically targeted. Our studies have revealed the complex network of interactions that are necessary to ensure an orderly progression through each of the steps of transcription initiation. We continue to study the functions of these transcription factors.

The core promoter is defined as the segment of DNA where gene transcription initiates. A series of conserved DNA sequence elements, alone or in combination, are thought to comprise the core promoter and be essential for promoter activity. In parallel studies on core promoter architecture, we demonstrated that none of the canonical core promoter elements are necessary for expression in vivo of a major histocompatibility class I gene, challenging the prevailing dogma that these elements are critical for promoter function. Rather, each plays a distinct role in promoter activity, chromatin structure, tissue-specific expression and extracellular signaling. In those tissues where mutation of the elements affects promoter activity, it results in increased activity. These findings lead to the surprising conclusion that core promoter elements can function as negative regulators of transcription. Our current studies are focused on characterizing the mechanistic effects of the core promoter mutations on transcription.

Expression of MHC class I genes, which the lab studies as a model of genes subject to both tissue-specific and hormonal regulatory mechanisms, is regulated, only in part, by epigenetic mechanisms. Thus, nucleosomal occupancy does not regulate expression: the promoter is in an open conformation, independent of transcription. However, boundary element located 3 prime to the gene maintains the gene in a euchromatic conformation by protecting it from heterochromatinization. Ongoing studies are focused on characterizing additional epigenetic control mechanisms.

We continue to study, and integrate, each of these three areas to achieve a comprehensive understanding of MHC class I transcriptional regulation.

Scientific Focus Areas:
Chromosome Biology, Immunology, Molecular Biology and Biochemistry

View Dr. Singer's PubMed Summary.

Selected Recent Publications
  1. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims RJ, Singer DS.
    Proc. Natl. Acad. Sci. U.S.A. 109: 6927-32, 2012. [ Journal Article ]
  2. Gegonne A, Tai X, Zhang J, Wu G, Zhu J, Yoshimoto A, Hanson J, Cultraro C, Chen Q, Guinter T, Yang Z, Hathcock K, Singer A, Rodriguez-Canales J, Tessarollo L, Mackem S, Meerzaman D, Buetow K, Singer DS.
    Mol. Cell. Biol. 32: 1984-97, 2012. [ Journal Article ]
  3. Barbash ZS, Weissman JD, Campbell JA, Mu J, Singer DS.
    Mol. Cell. Biol. 33: 4395-407, 2013. [ Journal Article ]
  4. Devaiah BN, Singer DS.
    J. Biol. Chem. 287: 38755-66, 2012. [ Journal Article ]
  5. Mu J, Tai X, Iyer SS, Weissman JD, Singer A, Singer DS.
    J. Immunol. 192: 2892-903, 2014. [ Journal Article ]

Dr. Dinah Singer has served as the Director of the Division of Cancer Biology (DCB), National Cancer Institute (NCI), National Institutes of Health (NIH), since 1999, while simultaneously serving as Senior Investigator and Chief of the Molecular Regulation Section of the Experimental Immunology Branch, NCI. After receiving her B.S. from the Massachusetts Institute of Technology and her Ph.D. from Columbia University, Dr. Singer was a postdoctoral fellow in the Laboratory of Biochemistry, NCI, and a senior investigator in the Immunology Branch, NCI. She serves on a number of scientific and advisory boards, is a member of the American Association of Immunologists and the American Association of Cancer Researchers, and has served as a Senior Science Officer at the Howard Hughes Medical Institute. Her research interests are in the areas of regulation of transcription, gene expression and molecular immunology. Dr. Singer serves in leadership positions on a variety of trans-NIH scientific and administrative committees, including NIH Common Fund initiatives. She has trained a large number of post-doctoral fellows, post-baccalaureate students and high school students who have gone on to successful scientific careers.

Name Position
Devaiah Ballachanda Ph.D. Postdoctoral Fellow (Visiting)
John Campbell Ph.D. Postbaccalaureate Fellow
Chanelle Case Postdoctoral Fellow (CRTA)
Dan Chen Postdoctoral Fellow (CRTA)
Anne Gegonne Ph.D. Staff Scientist
Oliver Hendy Postbaccalaureate Fellow
Sabina Hlavaty Postbaccalaureate Fellow
Jie Mu Ph.D. Research Biologist
Sheetal Uppal Postdoctoral Fellow (CRTA)
Jocelyn Weissman Research Chemist

Research

Molecular Mechanisms Regulating Gene Expression

The long-term goal of our research program is to define the molecular mechanisms regulating gene expression. To that end, the lab focuses on three main areas: 1) analyses of the factors and regulatory mechanisms that govern transcription initiation; 2) core promoter architecture and function in constitutive and activated transcription; 3) the role of epigenetic regulation.

Transcription initiation requires the assembly of a preinitiation complex (PIC), consisting of a set of general transcription factors and RNA polymerase II. The conventional understanding is that the PIC and its components are invariant among genes and cells. However, in studies on regulatory transcription factors, we discovered that the usage of general transcription factors varies in response to extracellular signals. Thus, whereas constitutive expression of a major histocompatibility (MHC) class I gene depends on the general transcription factor TFIID, γ-interferon activated transcription depends instead on the cofactor CIITA, which bypasses the requirement for TFIID. These studies demonstrated the dynamic nature of the factors regulating transcription initiation. This point was further demonstrated in subsequent studies from the lab which discovered a novel role for the TFIID component, TAF7, independent of its interaction with TFIID. Through its interactions with the kinases that phosphorylate RNA polymerase II, TAF7 regulates early steps of transcription.

In recent studies, we discovered that BRD4, a bromodomain family member currently being tested as a therapeutic target in cancer and autoimmune diseases, is a RNA polymerase II kinase essential for transcription. Our studies demonstrated that BRD4 plays a critical role in regulating the early steps of transcription initiation, both through its direct phosphorylation of RNA polymerase II and its interactions with other components of the transcription machinery, including TAF7. These findings suggest novel ways in which BRD4 might be therapeutically targeted. Our studies have revealed the complex network of interactions that are necessary to ensure an orderly progression through each of the steps of transcription initiation. We continue to study the functions of these transcription factors.

The core promoter is defined as the segment of DNA where gene transcription initiates. A series of conserved DNA sequence elements, alone or in combination, are thought to comprise the core promoter and be essential for promoter activity. In parallel studies on core promoter architecture, we demonstrated that none of the canonical core promoter elements are necessary for expression in vivo of a major histocompatibility class I gene, challenging the prevailing dogma that these elements are critical for promoter function. Rather, each plays a distinct role in promoter activity, chromatin structure, tissue-specific expression and extracellular signaling. In those tissues where mutation of the elements affects promoter activity, it results in increased activity. These findings lead to the surprising conclusion that core promoter elements can function as negative regulators of transcription. Our current studies are focused on characterizing the mechanistic effects of the core promoter mutations on transcription.

Expression of MHC class I genes, which the lab studies as a model of genes subject to both tissue-specific and hormonal regulatory mechanisms, is regulated, only in part, by epigenetic mechanisms. Thus, nucleosomal occupancy does not regulate expression: the promoter is in an open conformation, independent of transcription. However, boundary element located 3 prime to the gene maintains the gene in a euchromatic conformation by protecting it from heterochromatinization. Ongoing studies are focused on characterizing additional epigenetic control mechanisms.

We continue to study, and integrate, each of these three areas to achieve a comprehensive understanding of MHC class I transcriptional regulation.

Scientific Focus Areas:
Chromosome Biology, Immunology, Molecular Biology and Biochemistry

Publications

View Dr. Singer's PubMed Summary.

Selected Recent Publications
  1. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims RJ, Singer DS.
    Proc. Natl. Acad. Sci. U.S.A. 109: 6927-32, 2012. [ Journal Article ]
  2. Gegonne A, Tai X, Zhang J, Wu G, Zhu J, Yoshimoto A, Hanson J, Cultraro C, Chen Q, Guinter T, Yang Z, Hathcock K, Singer A, Rodriguez-Canales J, Tessarollo L, Mackem S, Meerzaman D, Buetow K, Singer DS.
    Mol. Cell. Biol. 32: 1984-97, 2012. [ Journal Article ]
  3. Barbash ZS, Weissman JD, Campbell JA, Mu J, Singer DS.
    Mol. Cell. Biol. 33: 4395-407, 2013. [ Journal Article ]
  4. Devaiah BN, Singer DS.
    J. Biol. Chem. 287: 38755-66, 2012. [ Journal Article ]
  5. Mu J, Tai X, Iyer SS, Weissman JD, Singer A, Singer DS.
    J. Immunol. 192: 2892-903, 2014. [ Journal Article ]

Biography

Dr. Dinah Singer has served as the Director of the Division of Cancer Biology (DCB), National Cancer Institute (NCI), National Institutes of Health (NIH), since 1999, while simultaneously serving as Senior Investigator and Chief of the Molecular Regulation Section of the Experimental Immunology Branch, NCI. After receiving her B.S. from the Massachusetts Institute of Technology and her Ph.D. from Columbia University, Dr. Singer was a postdoctoral fellow in the Laboratory of Biochemistry, NCI, and a senior investigator in the Immunology Branch, NCI. She serves on a number of scientific and advisory boards, is a member of the American Association of Immunologists and the American Association of Cancer Researchers, and has served as a Senior Science Officer at the Howard Hughes Medical Institute. Her research interests are in the areas of regulation of transcription, gene expression and molecular immunology. Dr. Singer serves in leadership positions on a variety of trans-NIH scientific and administrative committees, including NIH Common Fund initiatives. She has trained a large number of post-doctoral fellows, post-baccalaureate students and high school students who have gone on to successful scientific careers.

Team

Name Position
Devaiah Ballachanda Ph.D. Postdoctoral Fellow (Visiting)
John Campbell Ph.D. Postbaccalaureate Fellow
Chanelle Case Postdoctoral Fellow (CRTA)
Dan Chen Postdoctoral Fellow (CRTA)
Anne Gegonne Ph.D. Staff Scientist
Oliver Hendy Postbaccalaureate Fellow
Sabina Hlavaty Postbaccalaureate Fellow
Jie Mu Ph.D. Research Biologist
Sheetal Uppal Postdoctoral Fellow (CRTA)
Jocelyn Weissman Research Chemist